4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• 4D Molecular Therapeutics, Inc. has received a consensus recommendation of "Moderate Buy" from ten brokerages, with an average price target of $30.40.
• Despite the overall positive sentiment, one analyst has a sell rating on the stock, while eight analysts have assigned a buy rating.
• The company recently reported a loss of $0.98 per share for the last quarter, which was below analysts' expectations, alongside minimal revenue of $0.01 million.

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $30.40.

Several analysts have issued reports on the company. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Saturday, September 27th. Roth Capital cut their price objective on 4D Molecular Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Tuesday, August 12th. Finally, Chardan Capital restated a "buy" rating and set a $25.00 target price on shares of 4D Molecular Therapeutics in a research note on Tuesday, August 12th.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of 4D Molecular Therapeutics by 7.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company's stock valued at $247,000 after acquiring an additional 2,925 shares in the last quarter. Wellington Management Group LLP boosted its stake in 4D Molecular Therapeutics by 6.7% in the 4th quarter. Wellington Management Group LLP now owns 177,279 shares of the company's stock worth $987,000 after purchasing an additional 11,089 shares during the period. Harbor Capital Advisors Inc. purchased a new stake in 4D Molecular Therapeutics during the 1st quarter valued at approximately $99,000. Peapod Lane Capital LLC raised its position in shares of 4D Molecular Therapeutics by 35.3% during the first quarter. Peapod Lane Capital LLC now owns 195,853 shares of the company's stock valued at $633,000 after buying an additional 51,110 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $41,000. Hedge funds and other institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Trading Down 0.7%

Shares of FDMT stock opened at $8.67 on Friday. 4D Molecular Therapeutics has a 12 month low of $2.23 and a 12 month high of $10.56. The stock has a market cap of $404.89 million, a P/E ratio of -2.46 and a beta of 2.93. The company has a 50 day simple moving average of $6.65 and a two-hundred day simple moving average of $4.70.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.10). The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%. As a group, equities analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.